How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,014 results for

Topical Ointment

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial

The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial The safety and scientific validity of this study

2013 Clinical Trials

102. The safety and efficacy of topical retapamulin ointment versus placebo ointment in the treatment of secondarily infected traumatic lesions: a randomized, double-blind superiority study. (PubMed)

The safety and efficacy of topical retapamulin ointment versus placebo ointment in the treatment of secondarily infected traumatic lesions: a randomized, double-blind superiority study. To evaluate whether retapamulin 1% is clinically superior to a placebo in the treatment of patients with secondarily infected traumatic lesions.The study was a double-blind, placebo-controlled, parallel-group, phase 3 study.Patients were recruited from 5 countries.The aforementioned patients were all 2 months

2013 Advances in skin & wound care

103. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (UK National Health Servi

assessment for children. Measure of benefit: The measure of benefit was quality-adjusted life-years (QALYs). Cost data: The direct medical costs included the tacrolimus ointment, consultant dermatology and out-patient visits, phototherapy, topical steroids, oral medications, and in-patient stays. Published sources were used to measure and value these resources. These included MIMS 2009, NHS National Reference Costs, and the Personal Social Services Research Unit 2008. The costs of discontinuing (...) simulations at the acceptability threshold of £30,000 per QALY. Authors' conclusions The authors concluded that maintenance therapy, using tacrolimus ointment, for children and adults with moderate or severe atopic dermatitis, produced additional health benefits, at lower costs, and was cost-effective, compared with reactive treatment. CRD commentary Interventions: The two strategies were well described. It was unclear why topical corticosteroids and topical calcineurin inhibitors were not analysed, given

2011 NHS Economic Evaluation Database.

104. Efficacy of topical alpha ointment (containing natural henna) compared to topical hydrocortisone (1%) in the healing of radiation-induced dermatitis in patients with breast cancer: a randomized controlled clinical trial. (PubMed)

Efficacy of topical alpha ointment (containing natural henna) compared to topical hydrocortisone (1%) in the healing of radiation-induced dermatitis in patients with breast cancer: a randomized controlled clinical trial. This two-arm, randomized clinical study aimed to compare efficacy between topical Alpha ointment and topical hydrocortisone cream (1%) in the healing of radiation-induced dermatitis in breast cancer patients.The inclusion criteria comprised newly pathologically proven, locally (...) advanced breast cancer (treated with modified radical mastectomy followed by sequential adjuvant treatments, including chest wall radiotherapy [45-50.4 Gy]) and grade 2 and/or 3 chest wall dermatitis. The exclusion criteria were comprised of any underlying disease or medications interfering with the wound healing process, previous history of chest wall radiotherapy, and concurrent use of chemotherapy. Sixty eligible patients were randomly assigned to use either topical Alpha ointment (study arm, n=30

Full Text available with Trip Pro

2013 Iranian journal of medical sciences

105. Topical steroids better than vitamin D for treating scalp psoriasis

, but the difference was not considered clinically important. The combination ointment costs almost £20 for 30g compared to a 30g tube of typical steroid ointment which costs about £4. Scalp psoriasis is a common condition that can be itchy and embarrassing for many. A variety of topical lotions, solutions or gels are available to treat the condition, so this review of published research aimed to help doctors and patients find out which was the most effective and safest option. This systematic review found 59 (...) . In extreme cases it can cause hair loss, although this is usually only temporary. Topical treatments (creams and ointments for the skin) such as corticosteroids (steroids) and vitamin D are usually the first treatments tried, but applying them to the scalp is difficult because of hair on the head. It is also not clear which works best. This study aimed to help doctors and patients decide which of the wide variety of topical treatments available work best, and the type and frequency of any side effects

2018 NIHR Dissemination Centre

106. Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis

Completion Date : June 2017 Actual Study Completion Date : June 2017 Resource links provided by the National Library of Medicine related topics: related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: 0.3% OPA-15406 Ointments Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily. Drug: OPA-15406 Experimental: 1% OPA-15406 Ointments Subjects were treated with assigned 1% OPA-15406 ointment twice daily. Drug: OPA-15406 Placebo Comparator: Placebo Ointments (...) Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding

2017 Clinical Trials

107. Study of SOR007 Ointment for Actinic Keratosis

Phase 2 Detailed Description: In this Phase 2, randomized, double-blind, dose rising trial, subjects with actinic keratosis will receive topical application of SOR007 Ointment (in four concentrations) or SOR007 Ointment vehicle to the face twice daily for up to 28 days. Subjects will be enrolled in four dose-escalating cohorts of eight subjects and randomized to SOR0007 or Ointment vehicle in a ratio of 3:1. Cohorts will be enrolled sequentially starting at the lowest concentration. Safety (...) links provided by the National Library of Medicine resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: SOR007 0.15% SOR007 Ointment 0.15% applied to the face twice daily for 28 days Drug: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment SOR007 will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of SOR007 that will be applied daily will be 1 finger-tip unit (FTU

2017 Clinical Trials

108. A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp (AK004)

Ointment 1% Drug: Placebo Phase 3 Detailed Description: This study will be a double-blinded, multicenter, activity, and safety study of KX2-391 Ointment administered topically to the face or scalp of subjects with actinic keratosis. The study consists of Screening, Treatment, Follow-up, and Recurrence Follow-up Periods. Eligible subjects will receive X consecutive days of topical treatment, to be applied at the study site. Activity (lesion counts) and safety evaluations will be performed. Study Design (...) A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp (AK004) A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp (AK004) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2017 Clinical Trials

109. A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp

Phase 3 Detailed Description: This study will be a double-blinded, multicenter, activity, and safety study of KX2-391 Ointment administered topically to the face or scalp of subjects with actinic keratosis. The study consists of Screening, Treatment, Follow-up, and Recurrence Follow-up Periods. Eligible subjects will receive X consecutive days of topical treatment, to be applied at the study site. Activity (lesion counts) and safety evaluations will be performed. Study Design Go to Layout table (...) A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2017 Clinical Trials

110. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. (PubMed)

Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. Long-term topical treatment is often required for atopic dermatitis (AD), a chronic inflammatory skin disease.To assess the long-term safety results from a multicenter, open-label, 48-week safety study (AD-303) of patients (N = 517) ≥2 years of age with mild to moderate AD who continued crisaborole treatment, a topical phosphodiesterase-4 inhibitor, after completing a 28-day phase 3 (...) of TEAEs were consistent. The most frequently reported treatment-related AEs (overall, 10.2%) were dermatitis atopic (3.1%), application-site pain (2.3%), and application-site infection (1.2%). Nine patients (1.7%) discontinued the long-term study because of TEAEs.Long-term efficacy was not analyzed.Crisaborole ointment had a low frequency of treatment-related AEs over 48 weeks of treatment of patients with AD.Copyright © 2017 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights

Full Text available with Trip Pro

2017 Journal of American Academy of Dermatology

111. Percutaneous Posterior Tibial Nerve Stimulation vs Perianal Application of Glyceryl Trinitrate Ointment in the Treatment of Chronic Anal Fissure: A Randomized Clinical Trial. (PubMed)

Percutaneous Posterior Tibial Nerve Stimulation vs Perianal Application of Glyceryl Trinitrate Ointment in the Treatment of Chronic Anal Fissure: A Randomized Clinical Trial. Current therapeutic guidelines for the treatment of chronic anal fissure establish a medical approach as the first step. Glyceryl trinitrate ointment is the most popular of the available topical treatments in Spain but it is associated with the appearance of headache.The purpose of this study was to compare the compliance (...) rate among patients receiving glyceryl trinitrate treatment for chronic anal fissure with that among patients receiving percutaneous posterior tibial nerve stimulation.This was a prospective randomized study.The study was conducted at Garcilaso Clinic (Madrid, Spain).Subjects with persistent anal fissure despite hygiene and dietary measures applied over at least a 6-week period were included.Study interventions were perianal application of glyceryl trinitrate ointment (twice daily for 8 weeks

2017 Diseases of the Colon & Rectum

112. Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis. (PubMed)

Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis. Crisaborole ointment 2% (Eucrisa™) is a novel, anti-inflammatory inhibitor of phosphodiesterase 4 (PDE4) that is available in the USA for the topical treatment of mild to moderate atopic dermatitis in patients aged ≥ 2 years. In two short-term (28 days), identically designed, multicentre, phase III studies in this patient population, topical therapy with crisaborole ointment 2% reduced disease severity and pruritus (...) of mild to moderate severity and considered unrelated to the study medication. Moreover, the incidence of application-site pain following short- and longer-term topical therapy with crisaborole ointment 2% was low. In conclusion, crisaborole ointment 2% is an effective and generally well tolerated new topical option for the management of mild to moderate atopic dermatitis in patients aged ≥ 2 years, with the potential to effectively treat this patient population over the longer term without the safety

2017 American journal of clinical dermatology

113. Low incidence of hypercalcemia following combined calcipotriol hydrate/betamethasone dipropionate ointment treatment in Japanese patients with severe psoriasis vulgaris. (PubMed)

Low incidence of hypercalcemia following combined calcipotriol hydrate/betamethasone dipropionate ointment treatment in Japanese patients with severe psoriasis vulgaris. Topical active vitamin D3 application alone or in combination with topical steroid application is widely used to treat psoriasis. In Japan, combined calcipotriol hydrate/betamethasone dipropionate ointment has been used for patients with psoriasis vulgaris since September 2014. Current evidence regarding the incidence (...) Ca concentration changed only marginally, from 9.04 ± 0.34 mg/dL before treatment to 9.08 ± 0.39 mg/dL after 8 weeks of treatment. None of the patients had an elevated serum Ca concentration throughout the study. No cases of hypercalcemia were reported as an adverse event. No correlation was detected between the amount of the combined calcipotriol hydrate/betamethasone dipropionate ointment applied and changes in the serum Ca concentration.The incidence of hypercalcemia due to topical application

2017 Journal of Dermatological Treatment

114. Comparison of indirubin concentrations in indigo naturalis ointment for psoriasis treatment: a randomized, double-blind, dosage-controlled trial. (PubMed)

Comparison of indirubin concentrations in indigo naturalis ointment for psoriasis treatment: a randomized, double-blind, dosage-controlled trial. Indigo naturalis and its refined formulation, Lindioil, are effective in treating psoriatic symptoms topically. Indirubin is the active ingredient in indigo naturalis.To determine the efficacy and safety of different concentrations of indirubin in Lindioil ointment for treating psoriasis.In this randomized, double-blind trial, adult patients (...) ) was the 200 μg g-1 group. No severe treatment-related adverse events were reported during the 20-week evaluation.An amount of 200 μg g-1 of indirubin in Lindioil ointment is the most effective concentration studied so far for treating psoriasis topically, and is safe.© 2017 British Association of Dermatologists.

Full Text available with Trip Pro

2017 British Journal of Dermatology

115. Clinical safety and efficacy of vitamin D3 analog ointment for treatment of obstructive meibomian gland dysfunction. (PubMed)

as BUT, meibum grade, and meibomian gland area were significantly improved in oMGD patients after the 8-week treatment period compared with pretreatment values (P values of <0.001, 0.020, 0.030, 0.020, and 0.017, respectively).Topical eyelid application of an analog of the active form of vitamin D3 was found to be safe as well as to improve the condition of patients with oMGD. Such ointment thus warrants further evaluation as a potential new treatment option for this condition.This study was registered (...) Clinical safety and efficacy of vitamin D3 analog ointment for treatment of obstructive meibomian gland dysfunction. Hyperkeratinization is a major cause of obstructive meibomian gland dysfunction (oMGD) and results in degenerative gland dilation and atrophy without inflammation. Ointment containing 1,25-dihydroxy-22-oxavitamin D3 (maxacalcitol), a noncalcemic analog of the active form of vitamin D3, is applied for the treatment of hyperkeratotic cutaneous conditions such as psoriasis

Full Text available with Trip Pro

2017 BMC Ophthalmology

116. A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis

OF CRISABOROLE OINTMENT 2% IN CHILDREN AGED 3 MONTHS TO LESS THAN 24 MONTHS WITH MILD TO MODERATE ATOPIC DERMATITIS Actual Study Start Date : January 16, 2018 Estimated Primary Completion Date : April 11, 2019 Estimated Study Completion Date : April 11, 2019 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Crisaborole ointment 2% Subjects will be dosed for 28 days. A thin layer (...) A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2017 Clinical Trials

117. The Effect of Low-Dose Nitroglycerin Ointment on Skin Flap Necrosis in Breast Reconstruction after Skin-Sparing or Nipple-Sparing Mastectomy (PubMed)

The Effect of Low-Dose Nitroglycerin Ointment on Skin Flap Necrosis in Breast Reconstruction after Skin-Sparing or Nipple-Sparing Mastectomy Skin flap necrosis is a common complication after mastectomy and breast reconstruction. It has been proven that nitroglycerin ointment, as a topical vasodilator, can decrease the rate of skin flap necrosis after mastectomy and breast reconstruction. However, nitroglycerin can cause several side effects, including headache, dizziness, and hypotension (...) . The purpose of this study was to evaluate whether the application of a low dose of nitroglycerin ointment reduced the rate of skin flap necrosis in breast reconstruction after skin-sparing or nipple-sparing mastectomy.A total of 73 cases of breast reconstruction after nipple-sparing and skin-sparing mastectomy at our institution from March 2012 to January 2017 were retrospectively studied. Of these patients, 52 received nitroglycerin ointment (4.5 mg) application to the skin around the nipple-areolar

Full Text available with Trip Pro

2017 Archives of plastic surgery

118. A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis

-controlled, Parallel-cohort Study Of Crisaborole Ointment 2% To Evaluate The Skin Irritation Potential In Adult Japanese Healthy Subjects, And To Evaluate The Safety, Tolerability And Pharmacokinetics In Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis Actual Study Start Date : September 13, 2017 Actual Primary Completion Date : November 27, 2017 Actual Study Completion Date : November 27, 2017 Resource links provided by the National Library of Medicine related topics: related topics (...) A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study

2017 Clinical Trials

119. Efficacy Of Autologous Epidermal Cell Suspension And Silver Sulfadiazine Ointment In Burn

Efficacy Of Autologous Epidermal Cell Suspension And Silver Sulfadiazine Ointment In Burn Efficacy Of Autologous Epidermal Cell Suspension And Silver Sulfadiazine Ointment In Burn - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Efficacy Of Autologous Epidermal Cell Suspension And Silver Sulfadiazine Ointment In Burn The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03162367 Recruitment Status : Not yet recruiting First

2017 Clinical Trials

120. Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis

Study Start Date : July 31, 2017 Actual Primary Completion Date : May 4, 2018 Actual Study Completion Date : May 4, 2018 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Crisaborole ointment Drug: Crisaborole ointment 2% BID Crisaborole ointment 2% BID for 15 days (double blind); additional 28 days (open label) Placebo Comparator: Placebo ointment (vehicle) Drug: Placebo (...) corticosteroids or systemic (oral/injectable) corticosteroids to manage AD. History of angioedema or anaphylaxis to topical products or known sensitivity to components of crisaborole ointment 2%. History of cancer (except squamous or basal cell carcinoma or carcinoma in situ of the skin). Previous treatment with any topical or systemic PDE4 inhibitor unless stopped for the reason of lack of efficacy. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>